Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: A cost comparison

Clinical Colorectal Cancer

Volumn 9, Issue 4, 2010, Pages 229-237

  Chu, Edward ^a   Schulman, Kathy L ^b   McKenna, Edward F ^c   Cartwright, Thomas ^d  

^a YALE CANCER CENTER   (United States)

^b THOMSON REUTERS   (United Kingdom)

^c HOFFMANN LA ROCHE INC   (United States)

^d Ocala Oncology   (United States)

Author keywords

Charlson Comorbidity Index; Infusion administration; Pharmacoeconomics

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACQUIRED HEMOLYTIC ANEMIA; ADULT; ADVANCED CANCER; AGRANULOCYTOSIS; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CELLULITIS; CHLAMYDIASIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONSTIPATION; COUGHING; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DUODENITIS; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; GASTRITIS; GLOSSITIS; HEADACHE; HEALTH CARE COST; HERPETIC STOMATITIS; HUMAN; HYPERHIDROSIS; INSOMNIA; INTESTINE INFECTION; INTESTINE TUBERCULOSIS; IRON DEFICIENCY ANEMIA; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MONOTHERAPY; MOUTH ABSCESS; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NIGHT SWEAT; PARASITOSIS; PNEUMONIA; POLIOMYELITIS; PROPORTIONAL HAZARDS MODEL; RASH; SEPSIS; SIDE EFFECT; SPONTANEOUS PNEUMOTHORAX; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VIRUS INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 77957785821     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.034     Document Type: Article

References (35)

1. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007; 25:180-6.
2. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT Trial. Br J Cancer 2006; 94:1122-9.
3. Cassata A, Procoplo G, Alu M, et al. Capecitabine: indications and future per-spectives in the treatment of metastatic colorectal and breast cancer. Tumori 2001; 87:364-71.
4. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25:4-12.
5. Lee JJ, Chu E.An update on treatment advances for the first-line therapy of meta-static colorectal cancer. Cancer J 2007; 13:276-82.
6. Carrato A, Gallego-Plazas J, Guillen-Ponce C. Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Rev Anticancer Ther 2008; 8:161-74.
7. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intra-venous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-106.
8. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus in-travenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-92.
9. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxali-platin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006-12.
10. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19:1720-6.
11. Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer 2006; 6:278-87.
12. Delea TE, Vera-Llonch M, Edelsberg JS, et al. The incidence and cost of hospital-ization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 2002; 5:35-43.
13. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22:3524-30.
14. Partridge AH, La Fountain A, Mayer E, et al. Adherence to initial adjuvant anas-trozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26:556-62.
15. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007; 109:2334-42.
16. Kuehn BM. Better osteoporosis management a priority: impact predicted to soar with aging population. JAMA 2005; 293:2453-8.
17. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA 2005; 294:797-802.
18. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 6th ed. New York: Springer; 2001.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9.
20. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45:197-203.
21. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006; 9:377-85.
22. Baser O. Choosing propensity score matching over regression adjustment for causal inference: when, why and how it makes sense. J Media Econ 2007; 10:379-91.
23. US Bureau of Labor Statistics. Consumer Price Index: December 2007. Washington, DC: US Department of Labor, Bureau of Labor Statistics; 2007.
24. Cassidy J, Rothenberg M, Saltz L, et al. Meta-analysis of overall survival in 6 ran-domised phase III clinical trials of capecitabine vs. 5-FU in colorectal and gastric cancer. Presented at the 10th World Congress on Gastrointestinal Cancer; June 25-28, 2008; Barcelona, Spain.
25. Douillard JY, Tilleul P, Ychou M, et al. Cost consequences of adjuvant capecitabi-ne, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 2007; 72:248-54.
26. Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006; 95:1195-201.
27. Chu E, Schulman KL, Zelt S, et al. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer 2009; 115:1412-23.
28. Chu E, Shi N, Wei W, et al. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. Oncology 2009; 77:244-53.
29. Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 25:4165-7.
30. Chu E, Cartwright TH. Pharmacoeconomic benefits of capecitabine-based che-motherapy in metastatic colorectal cancer. J Clin Oncol 2008; 26:2224-6.
31. Garrison L, Best J, Cassidy J, et al. Cost comparison of XELOX vs. FOLFOX-4 ± bevacizumab in metastatic colorectal cancer. Presented at the 43rd Annual Meet-ing of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL.
32. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a random-ized crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38:349-58.
33. Twelves C, Gollins S, Grieve R, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patient with advanced colorectal cancer. Ann Oncol 2006; 17:239-45.
34. Pfeiffer P, Mortensen JP, Bjerregaard B, et al. Patient preference for oral or intra-venous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006; 42:2738-43.
35. Conroy T, Hebbar M, Bennouna J, et al. Quality-of-life findings from a ran-domised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer 2009; Epub ahead of print.